The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 23 , ISSUE 7 ( July, 2022 ) > List of Articles


Mucous Membrane Pemphigoid: A Case Report with Oral and Ocular Presentation

Hammam Ibrahim Fageeh

Keywords : Autoimmune, Mucous membrane pemphigoid, Topical corticosteroids, Vesiculobullous disease

Citation Information : Fageeh HI. Mucous Membrane Pemphigoid: A Case Report with Oral and Ocular Presentation. J Contemp Dent Pract 2022; 23 (7):755-759.

DOI: 10.5005/jp-journals-10024-3381

License: CC BY-NC 4.0

Published Online: 10-11-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Aim: To describe the diagnosis and management of mucous membrane pemphigoid (MMP) with oral and ocular presentation. Background: Mucous membrane pemphigoid constitutes a heterogeneous group of chronic, autoimmune vesiculobullous diseases characterized by blister formation that has a propensity to affect different mucous membranes of the body. The most commonly affected areas include the oral cavity, mucous membranes of the eyes, throat, genitalia, and nose. This disease usually affects elderly women with a peak incidence at around 50–70 years of age; however, rare cases have been diagnosed in children. The symptoms of MMP include recurrent blistering lesions which eventually rupture and occasionally heal with scarring that may lead to certain complications involving the eyes and throat regions. Case description: In this report, we describe a 66-year-old female patient who complained of oral and ocular lesions for a period of 2 years. Pain, burning mouth, and gingival inflammation were present. Ocular examination showed mild conjunctivitis with scar formation at the lateral canthus of the left eye. The patient also noticed periods of water-filled balloon-like formation in the gingiva that rupture spontaneously leaving sore spots. A biopsy was obtained from perilesional tissue and sent for histopathological examination, correlation of clinical and histological features directed us toward the diagnosis of MMP. The patient was treated for both oral and ocular lesions using topical corticosteroid therapy in conjunction with antifungal and antibacterial drugs. The response to local treatment was augmented via effective periodontal therapy to control the concurrent plaque-induced gingival inflammation and via using a customized application tray to sustain the drug efficacy. Conclusion: A multidisciplinary approach is often necessary in order to treat MMP lesions efficaciously. Clinical significance: Early diagnosis and effective treatment protocol using systemic or topical corticosteroid therapy along with other therapeutic means including periodontal therapy, good oral hygiene practice, and timely follow-up are very useful in preventing long-term complications due to this disease.

PDF Share
  1. National Organization for Rare Disorders (NORD). Mucous Membrane Pemphigoid. NORD – Rare disease Database. The Ohio state University College of Dentistry. Accessed on: March 29, 2016.
  2. Challacombe SJ, Setterfield J, Shirlaw P, et al. Immunodiagnosis of pemphigus and mucous membrane pemphigoid. Acta Odontol Scand 2001;59(4):226–234. DOI: 10.1080/00016350152509256.
  3. Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996;106(1):141–146. DOI: 10.1111/1523-1747.ep12329728.
  4. Kamaguchi M, Iwata H. The diagnosis and blistering mechanisms of mucous membrane pemphigoid. Front Immunol 2019;10:34: DOI: 10.3389/fimmu.2019.00034.
  5. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 1994;77(6):555–571. DOI: 10.1016/0030-4220(94)90312-3.
  6. Marteau J-M, Bercault B, Fenelon M, et al. Drug-induced oral mucous membrane pemphigoid: A case report. Médecine Buccale Chir Buccale 2017;23(4):181–183. DOI: 10.1051/mbcb/2017005.
  7. Bruch–Gerharz D, Hertl M, Ruzicka T. Mucous membrane pemphigoid: Clinical aspects, immunopathological features and therapy. Eur J Dermatol 17(3):191–200. DOI: 10.1684/ejd.2007.0148.
  8. Dharman S, Muthukrishnan A. Oral mucous membrane pemphigoid: Two case reports with varied clinical presentation. J Indian Soc Periodontol 20(6):630–634. DOI: 10.4103/jisp.jisp_155_16.
  9. Rashid H, Lamberts A, Diercks GFH, et al. Oral lesions in autoimmune bullous diseases: An overview of clinical characteristics and diagnostic algorithm. Am J Clin Dermatol [Internet]. 2019;20(6):847–861. DOI: 10.1007/s40257-019-00461-7.
  10. Maity S, Banerjee I, Sinha R, et al. Nikolsky's sign: A pathognomic boon. J Fam Med Prim care 2020;9(2):526–530. DOI: 10.4103/jfmpc.jfmpc_889_19.
  11. Bagan J, Muzio L, Scully C. Number III Mucous membrane pemphigoid. Oral Dis 2005;11(4):197–218. DOI: 10.1111/j.1601-0825.2005.01140.x.
  12. Vassileva S. Drug-induced pemphigoid. Clin Dermatol 1998;16(3):379–387. DOI: 10.1016/s0738-081x(98)00008-x.
  13. Fiore PM. Drug-induced pemphigoid. Arch Ophthalmo 1987;105(12): 1660. DOI: 10.1001/archopht.1987.01060120058023.
  14. Alkan A, Günhan O, Alkan A, et al. A clinical study of oral mucous membrane pemphigoid. J Int Med Res 31(4):340–344. DOI: 10.1177/147323000303100414.
  15. Kanjanabuch P, Arporniem S, Thamrat S, et al. Mucous membrane pemphigoid in a patient with hypertension treated with atenolol: A case report. J Med Case Rep 2012;6:373. DOI: 10.1186/1752-1947-6-373.
  16. McKee PH. The diagnosis of auto-immune-mediated acquired sub-epidermal blisters: variations on a theme. Curr Diagnostic Pathol 1997;4(1):10–19. DOI: 10.1016/S0968-6053(97)80003-8.
  17. Tofan EC, Părlătescu I, Ţovaru Ş, et al. Desquamative gingivitis: A clinicopathological review. Curr Heal Sci J 44(4):331–336. DOI: 10.12865/CHSJ.44.04.01.
  18. Mutasim DF, Pelc NJ, Supapannachart N. Established methods in the investigation of bullous diseases. Dermatol Clin 1993;11(3):399–418. PMID: 8365028.
  19. Goletz S, Probst C, Komorowski L, et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol 2019;180(1):149–156. DOI: 10.1111/bjd. 17202.
  20. Rogers RS, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982;6(2):215–223. DOI: 10.1016/s0190-9622(82)70014-3.
  21. Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol 1995;132(5):784–789. DOI: 10.1111/j.1365-2133.1995.tb00727.x.
  22. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000;43(4):571–591. DOI: 10.1067/mjd.2000.107248.
  23. Xu H-H, Werth VP, Parisi E, et al. Mucous membrane pemphigoid. Dent Clin North Am 2013;57(4):611–630. DOI: 10.1016/j.cden.2013.07.003.
  24. Damoulis PD, and Gagari E. Combined treatment of periodontal disease and benign mucous membrane pemphigoid. Case report with 8 years maintenance. Journal of Periodontology 2000;71(10): 1620–1629. DOI: 10.1902/jop.2000.71.10.1620.
  25. Garcia-Pola, MJ, Rodriguez-Lopez S, Fernanz-Vigil A, et al. Oral hygiene instructions and professional control as part of the treatment of desquamative gingivitis. Systematic review. Medicina oral, patologia oral y cirugia bucal 2019;24(2): e136–e144. DOI: 10.4317/medoral.22782.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.